Lowering apolipoprotein CIII delays onset of type 1 diabetes
2011 (English)In: Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, E-ISSN 1091-6490, Vol. 108, no 26, 10685-10689 p.Article in journal (Refereed) Published
Serum levels of apolipoprotein CIII (apoCIII) are increased in type 1 diabetic patients, and when β cells are exposed to these diabetic sera, apoptosis occurs, an effect abolished by an antibody against apoCIII. We have investigated the BB rat, an animal model that develops a human-like type 1 diabetes, and found that apoCIII was also increased in sera from prediabetic rats. This increase in apoCIII promoted β-cell death. The endogenous levels of apoCIII were reduced by treating prediabetic animals with an antisense against this apolipoprotein, resulting in a significantly delayed onset of diabetes. ApoCIII thus serves as a diabetogenic factor, and intervention with this apolipoprotein in the prediabetic state can arrest disease progression. These findings suggest apoCIII as a target for the treatment of type 1 diabetes.
Place, publisher, year, edition, pages
National Academy of Sciences , 2011. Vol. 108, no 26, 10685-10689 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:umu:diva-57947DOI: 10.1073/pnas.1019553108PubMedID: 21670290OAI: oai:DiVA.org:umu-57947DiVA: diva2:545984